A Phase 3 interventional study of Vadadustat and Mircera® in Anemia Associated With Chronic Kidney Disease (CKD), sponsored by Akebia Therapeutics. Completed at 58 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-15.
Sponsored by Akebia Therapeutics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing vadadustat in Anemia — 1 open to participants now, 1 under way, none of them phase 3. vadadustat · Anemia.
Among the 27 studies testing vadadustat in Anemia, this one is the 5th largest by enrollment, is the only one that started in 2021, is one of 14 in phase 3, and was the 23rd registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →1 of the 27 studies testing vadadustat in Anemia is open now. Recruiting first, the newest first:
Mackay Memorial Hospital
Ages 18+
vadadustat: first FDA approval 2024 (VAFSEO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2021.
This study's enrollment of 456 is above the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 60 across the 27 interventional studies. Of the 23 that completed or were terminated, 18 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 27 have an industry lead sponsor. The 4 most frequent:
Akebia Therapeutics is the lead sponsor of 37 studies on the registry; 3 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 12 (55%) have results posted.
23 studies in Anemia by Akebia Therapeutics: none open now, none under way, none of them phase 3. Of 20 finished, 16 (80%) have results posted.
Among the 23 studies in Anemia by Akebia Therapeutics, this one is the 4th largest by enrollment, is the only one that started in 2021, is one of 10 in phase 3, and was the 21st registered.
Akebia Therapeutics’s Anemia studies by the year they started, since 2010.
None of the studies under way reaches primary completion within a year.
Among the 27 studies testing vadadustat in Anemia, from their registry updates:
Among Akebia Therapeutics’s 23 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will be conducted to demonstrate the efficacy and safety of vadadustat administered three times weekly (TIW) compared to a long-acting erythropoiesis-stimulating agent (ESA) (Mircera®) for the maintenance treatment of anemia in hemodialysis participants.
Following randomization, there will be 2 periods during the study:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants previously receiving Mircera® received vadadustat for up to 52 weeks with an initial dose of 600 milligrams (mg).
Drug: Vadadustat
Participants previously receiving Mircera® received vadadustat for up to 52 weeks with an initial dose of 900 mg.
Drug: Vadadustat
Participants will continue to receive Mircera® for up to 52 weeks.
Drug: Mircera®
oral tablets
intravenous administration
Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Evaluation Period (PEP) (Weeks 20 to 26)
The Baseline Hb was defined as the average of last 2 central laboratory Hb measurements of samples taken at or prior to the first dose. The average for the PEP was calculated as the average of all Hb measurements from the central laboratory within the three visit windows during Weeks 20 through 26. Analysis was conducted using an analysis of covariance (ANCOVA) model with multiple imputation for missing data with randomization stratification factors and Baseline Hb as covariates. Change from Baseline was calculated as PEP value minus the Baseline value.
Time frame: Baseline; Weeks 20 to 26
Change From Baseline in Hb to the Average Over the Secondary Evaluation Period (SEP) (Weeks 46 to 52)
The Baseline Hb was defined as the average of the last 2 central laboratory Hb values taken on or prior to the first dose date. The average for the SEP was calculated as the average of all Hb measurements from the central laboratory within the three visit windows during Weeks 46 through 52. Analysis was conducted using an ANCOVA model with multiple imputation for missing data with randomization stratification factors and Baseline Hb as covariates. Change from Baseline was calculated as SEP value minus the Baseline value.
Time frame: Baseline; Weeks 46 to 52
This was a randomzied, open-label, active-controlled study of the efficacy and safety of conversion from long-acting Erythropoiesis-stimulating Agent (ESA) (Methoxy polyethylene glycol-epoetin beta \[Mircera®\]) to vadadustat Three Times Weekly (TIW) for the maintenance treatment of anemia in hemodialysis participants.
| Milestone | Vadadustat 600 mg TIW | Vadadustat 900 mg TIW | Mircera® |
|---|---|---|---|
| Started | 152 | 152 | 152 |
| Completed | 99 | 98 | 118 |
| Not completed | 53 | 54 | 34 |
| Withdrew: Adverse event | 9 | 18 | 3 |
| Withdrew: Investigator's discretion | 8 | 4 | 3 |
| Withdrew: Withdrawal by subject | 6 | 8 | 2 |
| Withdrew: Lack of efficacy | 1 | 3 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 3 |
| Withdrew: Death | 13 | 11 | 13 |
| Withdrew: Protocol violation | 2 | 1 | 0 |
| Withdrew: Non compliance with study drug | 1 | 0 | 0 |
| Withdrew: Transplant | 4 | 4 | 8 |
| Withdrew: Other | 9 | 5 | 2 |
The Baseline Hb was defined as the average of last 2 central laboratory Hb measurements of samples taken at or prior to the first dose. The average for the PEP was calculated as the average of all Hb measurements from the central laboratory within the three visit windows during Weeks 20 through 26. Analysis was conducted using an analysis of covariance (ANCOVA) model with multiple imputation for missing data with randomization stratification factors and Baseline Hb as covariates. Change from Baseline was calculated as PEP value minus the Baseline value.
| Grams per deciliter (g/dL) | Vadadustat 600 mg TIW | Vadadustat 900 mg TIW | Mircera® |
|---|---|---|---|
| Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Evaluation Period (PEP) (Weeks 20 to 26) | -0.07 ± 0.095 | 0.14 ± 0.095 | 0.36 ± 0.092 |
The Baseline Hb was defined as the average of the last 2 central laboratory Hb values taken on or prior to the first dose date. The average for the SEP was calculated as the average of all Hb measurements from the central laboratory within the three visit windows during Weeks 46 through 52. Analysis was conducted using an ANCOVA model with multiple imputation for missing data with randomization stratification factors and Baseline Hb as covariates. Change from Baseline was calculated as SEP value minus the Baseline value.
| Grams per deciliter | Vadadustat 600 mg TIW | Vadadustat 900 mg TIW | Mircera® |
|---|---|---|---|
| Change From Baseline in Hb to the Average Over the Secondary Evaluation Period (SEP) (Weeks 46 to 52) | -0.11 ± 0.110 | -0.22 ± 0.123 | 0.16 ± 0.102 |
Collected over Day 1 through Week 56. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vadadustat 600 mg TIW | 14/151 (9.3%) | 68/151 (45%) | 61/151 (40.4%) |
| Vadadustat 900 mg TIW | 12/150 (8%) | 66/150 (44%) | 67/150 (44.7%) |
| Mircera® | 17/150 (11.3%) | 67/150 (44.7%) | 64/150 (42.7%) |
| Event | Vadadustat 600 mg TIW | Vadadustat 900 mg TIW | Mircera® |
|---|---|---|---|
| Cardiac arrestCardiac disorders | 2/151 | 3/150 | 11/150 |
| COVID 19 pneumoniaInfections and infestations | 1/151 | 4/150 | 8/150 |
| PneumoniaInfections and infestations | 4/151 | 7/150 | 2/150 |
| HypervolaemiaMetabolism and nutrition disorders | 7/151 | 6/150 | 4/150 |
| COVID 19Infections and infestations | 3/151 | 5/150 | 6/150 |
| Acute myocardial infarctionCardiac disorders | 4/151 | 3/150 | 5/150 |
| HyperkalaemiaMetabolism and nutrition disorders | 4/151 | 4/150 | 5/150 |
| Arteriovenous graft thrombosisInjury, poisoning and procedural complications | 1/151 | 3/150 | 5/150 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 4/151 | 5/150 | 5/150 |
| Cardiac failure congestiveCardiac disorders | 5/151 | 2/150 | 1/150 |
| Event | Vadadustat 600 mg TIW | Vadadustat 900 mg TIW | Mircera® |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 16/151 | 21/150 | 11/150 |
| COVID 19Infections and infestations | 19/151 | 18/150 | 19/150 |
| NauseaGastrointestinal disorders | 12/151 | 13/150 | 7/150 |
| HyperkalaemiaMetabolism and nutrition disorders | 6/151 | 13/150 | 12/150 |
| FallInjury, poisoning and procedural complications | 11/151 | 8/150 | 11/150 |
| HypertensionVascular disorders | 5/151 | 4/150 | 11/150 |
| HeadacheNervous system disorders | 3/151 | 10/150 | 5/150 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 9/151 | 8/150 | 4/150 |
| Arteriovenous fistula site complicationInjury, poisoning and procedural complications | 7/151 | 8/150 | 7/150 |
| VomitingGastrointestinal disorders | 4/151 | 5/150 | 8/150 |
Randomized population included all randomized participants.
| Age, Continuous(Years) | Vadadustat 600 mg TIW | Vadadustat 900 mg TIW | Mircera® | Total |
|---|---|---|---|---|
| Mean | 59.4 ± 14.20 | 61.9 ± 13.27 | 61.6 ± 12.80 | 61.0 ± 13.45 |
| Sex: Female, Male(Participants) | Vadadustat 600 mg TIW | Vadadustat 900 mg TIW | Mircera® | Total |
|---|---|---|---|---|
| Female | 68 | 60 | 66 | 194 |
| Male | 84 | 92 | 86 | 262 |
| Ethnicity (NIH/OMB)(Participants) | Vadadustat 600 mg TIW | Vadadustat 900 mg TIW | Mircera® | Total |
|---|---|---|---|---|
| Hispanic or Latino | 42 | 40 | 56 | 138 |
| Not Hispanic or Latino | 110 | 109 | 95 | 314 |
| Unknown or Not Reported | 0 | 3 | 1 | 4 |
| Race (NIH/OMB)(Participants) | Vadadustat 600 mg TIW | Vadadustat 900 mg TIW | Mircera® | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 5 | 3 | 4 | 12 |
| Asian | 3 | 2 | 3 | 8 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 1 |
| Black or African American | 56 | 59 | 53 | 168 |
| White | 86 | 87 | 92 | 265 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2021 to primary completion in Jan 2023, 18 months.
Results were first posted in Jan 2025, 2 years after primary completion. A results delay was requested in Dec 2023.
Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 18 months is below that.
Counting every sponsor, half of 149 studies reached it within 30 months; a quarter within 17 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vadadustat